Inability of Plasmacytoid Dendritic Cells To Directly Lyse HIV-Infected Autologous CD4+ T Cells despite Induction of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand

The function of plasmacytoid dendritic cells (PDC) in chronic human immunodeficiency virus type 1 (HIV-1) infection remains controversial with regard to its potential for sustained alpha interferon (IFN-α) production and induction of PDC-dependent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity of HIV-infected cells. We address these areas by a study of chronically HIV-1-infected subjects followed through antiretroviral therapy (ART) interruption and by testing PDC cytolytic function against autologous HIV-infected CD4⁺ T cells. Rebound in viremia induced by therapy interruption showed a positive association between TRAIL and viral load or T-cell activation, but comparable levels of plasma IFN-α/β were found in viremic ART-treated and control subjects. While PDC from HIV-infected subjects expressed less interferon regulator factor 7 (IRF-7) and produced significantly less IFN-α upon Toll-like receptor 7/9 (TLR7/9) engagement than controls, membrane TRAIL expression in PDC from HIV⁺ subjects was increased. Moreover, no significant increase in death receptor 5 (DR5) expression was seen in CD4⁺ T cells from viremic HIV⁺ subjects compared to controls or following in vitro infection/exposure to infectious and noninfectious virus or exogenous IFN-α, respectively. Although activated PDC killed the DR5-expressing HIV-infected Sup-T1 cell line, PDC did not lyse primary autologous HIV⁺ CD4⁺ T cells yet could provide accessory help for NK cells in killing HIV-infected autologous CD4⁺ T cells. Taken together, our data show a lack of sustained high levels of soluble IFN-α in chronic HIV-1 infection in vivo and document a lack of direct PDC cytolytic activity against autologous infected or uninfected CD4⁺ T cells.Human immunodeficiency virus (HIV) infection is associated with chronic immune activation, progressive immune suppression, and deletion of memory adaptive responses, resulting in increased susceptibility to opportunistic infections (23, 51, 52). Loss of CD4⁺ T cells is the hallmark of HIV infection, with multiple mechanisms proposed as contributing to this loss (activation-induced cell death, direct cytopathic effect, immune cells, and death receptor-mediated apoptosis induction) (reviewed in references 33 and 34). One of the most puzzling observations in AIDS pathogenesis has been the progressive depletion of bystander T cells, especially in lymphoid tissues (25, 33, 34, 55). While antiretroviral therapy (ART) initiated in the early stages of HIV infection, when CD4⁺ T-cell counts are high (>500 cells/μl), may prevent the destruction of lymph node (LN) tissue and the massive depletion of CD4⁺ T lymphocytes by decreasing the rate of virally induced apoptosis (20), a persistent, albeit decreased, level of apoptosis of peripheral blood CD4⁺ and CD8⁺ T cells is seen in ART-treated HIV⁺ subjects despite long-term viral suppression (36).A member of the tumor necrosis factor (TNF) family, TNF-related apoptosis-inducing ligand (TRAIL), has been shown to be involved in HIV-1-associated T-cell apoptosis (33, 34). TRAIL (soluble or membrane bound) induces apoptosis upon binding to death receptor 4 (DR4; also named TRAIL-R1) or DR5 (also named TRAIL-R2, TRICK2, or Killer/DR5).On the basis of the in vitro observation that alpha interferon (IFN-α) and interferon regulator factor 7 (IRF-7) are increased in plasmacytoid dendritic cells (PDC) exposed to HIV-1 (40), the hypothesis that PDC activation by HIV-1 is responsible for an increased level of IFN-α throughout chronic disease has been proposed. It has also been proposed that the activation of the PDC compartment by HIV-1 participates in the initial immune activation following acute infection and contributes to CD4⁺ T-cell depletion by inducing, through IFN-α, the production of TRAIL, which mediates apoptosis of DR5-expressing CD4⁺ T cells following HIV-1 infection (37, 38, 40). However, several lines of evidence question the direct involvement of PDC in the loss of T cells during HIV infection, as PDC numbers are depleted during chronic HIV infection and PDC remaining in circulation are functionally impaired (10). Recent data show that circulating PDC in HIV-infected subjects, although unable to secrete IFN-α after Toll-like receptor (TLR)-mediated activation, constitutively express an increased level of IFN-α mRNA, indicating that during HIV infection PDC are activated yet impaired (71). Rodriguez et al. demonstrated the prevention of spontaneous apoptosis of CD4⁺ and CD8⁺ T cells by IFN-α (63), a major product of PDC following HIV-1 stimulation (3, 28). In addition, Audige et al. (2) showed that blockade of IFN-α and IFN-α receptor during in vitro HIV infection of CD4⁺ T cells isolated from human tonsils did not prevent apoptosis or TRAIL production, suggesting a lack of a central link between IFN-α production and apoptosis of tonsillar CD4⁺ T cells in HIV-1 infection. These data are also consistent with the observation that, in the human peripheral blood lymphocyte-transplanted SCID mouse (hu-PBL-SCID) model, IFN-α efficiently increases the survival of CD4⁺ T cells (49). Thus, controversy remains on the role of IFN-α as an indirect or direct inducer of apoptosis of CD4⁺ T cells through PDC/TRAIL induction, whereas the possibility that IFN-α acts as an antiviral agent by controlling HIV-1 replication and thus reducing virally mediated T-cell loss appears to be supported by several studies (reviewed in references 26, 47, and 58). In this regard, endogenous IFN-α produced by PDC has been shown to play an important role in controlling HIV infection in the human thymus (35), upregulating host antiviral factors such as APOBEC (1, 32, 44, 70) and stimulating NK cell-mediated cytotoxic activity against autologous HIV-infected targets (72).In this report, we investigated the in vivo correlates of viremia in chronically infected subjects by studying the relationship between therapy interruption-associated viremia and plasma IFN-α and TRAIL levels. We also tested in vitro the functional outcome of HIV-1-activated PDC in terms of their ability to mediate lysis of primary autologous CD4 T cells (infected or not with HIV-1), compared to indirect PDC-mediated lysis effects on the NK-dependent antiviral cytotoxic response.     

Association of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) with Central Adiposity and Low-Density Lipoprotein Cholesterol

Objective

Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL), in addition to having a prognostic value in patients with cardiovascular disease, seems to interact with adiposity, insulin resistance and other cardiovascular risk factors. However, the results of previous clinical studies, focused on the association of TRAIL with selected metabolic or anthropometric indices were inconclusive. The aim of this study was to further investigate how soluble TRAIL concentrations independently correlate with major cardiovascular risk factors, including lipid, glycemic and anthropometric features.

Materials/Methods

We examined the associations between serum soluble TRAIL concentrations, measured by ELISA, and lipid, glycemic and anthropometric features in 199 subjects recruited at our Metabolic Outpatient Clinic.

Results

Soluble TRAIL concentrations had a significant and direct correlation with total cholesterol (p = 0.046), LDL-cholesterol (p = 0.032), triglycerides (p = 0.01), body mass index (p = 0.046), waist circumference (p = 0.008), fat mass (p = 0.056) and insulin (p = 0.046) and an inverse correlation with HDL-cholesterol (p = 0.02). In multivariable regression analyses adjusted for potential confounders (age, gender, C-reactive protein, HDL-cholesterol, triglycerides, waist circumference, and insulin), TRAIL levels continued to have an independent correlation with LDL-cholesterol and waist circumference (r² = 0.04).

Conclusions

Serum TRAIL levels were weakly but significantly and independently associated with waist circumference, a marker of visceral adiposity, and with LDL-cholesterol. Further studies are needed to clarify the biological basis of these relationships.     

Isoegomaketone Induces Apoptosis through Caspase-Dependent and Caspase-Independent Pathways in Human DLD1 Cells

Isoegomaketone (IK) is an essential oil component of Perilla frutescens (L.), but the mechanism by which IK induces apoptosis has never been studied. The purpose of this study was to elucidate the IK-induced apoptotic pathway in DLD1 human colon cancer cells. We observed that IK treatment over 24 h significantly inhibited cell viability in a dose-dependent manner. We also found that IK triggered cleavage of PARP. Moreover, IK treatment resulted in cleavage of caspase-8, -9, and -3 in a dose- and time-dependent manner. IK treatment also resulted in cleavage of Bid and translocation of Bax, and triggered the release of cytochrome c from the mitochondria to the cytoplasm. Furthermore, it resulted in the translocation of apoptosis inducing factor (AIF), a caspase-independent mitochondrial apoptosis factor, from the mitochondria into the nucleus. Overall, these results suggest that IK induces apoptosis through caspase-dependent and capase-independent pathways in DLD1 cells.     

Improvement of Expression Level and Bioactivity of Soluble Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (Apo2L/TRAIL) by a Novel Zinc ion Feeding Strategy

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (Apo2L/TRAIL) is a new member of the TNF superfamily. In this work, the key role of Zn²⁺ in high-level expression of soluble TRAIL was confirmed. The yield of soluble TRAIL reached 1.6 g l⁻¹ using a novel, two-stage Zn²⁺ feeding strategy, and the accumulation of TRAIL inclusion bodies decreased. Furthermore, the purified TRAIL showed stronger cytotoxicity activity against human pancreatic 1990 tumor cells as the molar ratio of Zn²⁺ to TRAIL monomer was 2 in purified TRAIL solution.     

重组可溶性TRAIL的表达与生物学活性

研究重组可溶性TRAIL的抗肿瘤生物学活性。采用基因分子生物学方法构建重组可溶性TRAIL的表达载体,建立大肠杆菌表达菌株,采用柱层析等方法获得纯化的重组可溶性TRAIL;采用流式细胞术、细胞活性测定法和体内药效学实验分析重组可溶性TRAIL杀伤肿瘤细胞的生物学活性。结果表明重组可溶性TRAIL在体外可诱导人白血病细胞和肝癌细胞凋亡,凋亡率达50%以上。中枢神经系统的肿瘤细胞对重组可溶性TRAIL不敏感。重组可溶性TRAIL在体内能显著抑制人非小细胞肺癌细胞在小鼠体内生长,抑制率达70%以上。结论为研究制备的重组可溶性TRAIL能在体内外杀死多种肿瘤细胞,具有显著的临床应用前景。     

肿瘤坏死因子相关凋亡诱导配体的表达及其活性检测

目的:构建肿瘤坏死因子相关凋亡诱导配体(TRAIL)高表达工程菌株,以获得具有生物学活性的重组TRAIL蛋白.方法:合成TRAIL基因,转到大肠杆菌中,IPTG诱导获得成功表达;进一步优化,增加可溶形式的蛋白质.利用硫酸铵对发酵液进行沉淀,经Ni柱、阴离子和阳离子交换柱层析,最终获得蛋白质纯品,对其进行体外活性检测.结果:经过IPTG诱导后,TRAIL达到菌体总蛋白的30％;经过优化,可溶形式蛋白达到55％.纯化获得纯度高于95％的TRAIL样品,体外测活结果表明:TRAIL蛋白能有效抑制多种肿瘤细胞增殖,抑制率达到70％-92％.结论:重组TRAIL以可溶形式得到高效表达,且具有较好的生物学活性,为其开发成药用蛋白奠定基础.     

RHPS4 G-Quadruplex Ligand Induces Anti-Proliferative Effects in Brain Tumor Cells

Background

Telomeric 3′ overhangs can fold into a four-stranded DNA structure termed G-quadruplex (G4), a formation which inhibits telomerase. As telomerase activation is crucial for telomere maintenance in most cancer cells, several classes of G4 ligands have been designed to directly disrupt telomeric structure.

Methods

We exposed brain tumor cells to the G4 ligand 3,11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate (RHPS4) and investigated proliferation, cell cycle dynamics, telomere length, telomerase activity and activated c-Myc levels.

Results

Although all cell lines tested were sensitive to RHPS4, PFSK-1 central nervous system primitive neuroectodermal cells, DAOY medulloblastoma cells and U87 glioblastoma cells exhibited up to 30-fold increased sensitivity compared to KNS42 glioblastoma, C6 glioma and Res196 ependymoma cells. An increased proportion of S-phase cells were observed in medulloblastoma and high grade glioma cells whilst CNS PNET cells showed an increased proportion of G1-phase cells. RHPS4-induced phenotypes were concomitant with telomerase inhibition, manifested in a telomere length-independent manner and not associated with activated c-Myc levels. However, anti-proliferative effects were also observed in normal neural/endothelial cells in vitro and ex vivo.

Conclusion

This study warrants in vivo validation of RHPS4 and alternative G4 ligands as potential anti-cancer agents for brain tumors but highlights the consideration of dose-limiting tissue toxicities.     

Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-Troglitazone-induced Apoptosis in Prostate Cancer Cells Involve AMP-activated Protein Kinase

Prostate cancer (PCa) is one of the most frequently diagnosed cancers in men with limited treatment options for the hormone-resistant forms. Development of novel therapeutic options is critically needed to target advanced forms. Here we demonstrate that combinatorial treatment with the thiazolidinedione troglitazone (TZD) and TNF-related apoptosis-inducing ligand (TRAIL) can induce significant apoptosis in various PCa cells independent of androgen receptor status. Because TZD is known to activate AMP-activated protein kinase (AMPK), we determined whether AMPK is a molecular target mediating this apoptotic cascade by utilizing PCa cell lines stably overexpressing AMPKα1 dominant negative (C4-2-DN) or empty vector (C4-2-EV). Our results indicated a significantly higher degree of apoptosis with TRAIL-TZD combination in C4-2-EV cells compared with C4-2-DN cells. Similarly, results from a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay showed a larger reduction of viability of C4-2-EV cells compared with C4-2-DN cells when treated with TRAIL-TZD, thus suggesting that C4-2-DN cells were more apoptosis-resistant. Additionally, siRNA-mediated knockdown of endogenous AMPKα1 expression showed a reduction of TRAIL-TZD-induced apoptosis, further confirming the participation of AMPK in mediating this apoptosis. Apoptosis induction by this combinatorial treatment was also associated with a cleavage of β-catenin that was inhibited in both C4-2-DN cells and those cells in which AMPKα1 was knocked down. In addition, time course studies showed an increase in pACC^S79 (AMPK target) levels coinciding with the time of apoptosis. These studies indicate the involvement of AMPK in TRAIL-TZD-mediated apoptosis and β-catenin cleavage and suggest the possibility of utilizing AMPK as a therapeutic target in apoptosis-resistant prostate cancer.     

雷公藤甲素诱导胰腺癌细胞凋亡

目的：观察雷公藤甲素对胰腺癌细胞BxPC-3和PANC-1生长抑制及诱导细胞凋亡作用,探讨雷公藤甲素抗胰腺癌的机制。方法：雷公藤甲素处理BxPC-3和PANC—1细胞后,用M1rr法检测细胞的生长抑制,用流式细胞术检测细胞的凋亡率,用罗丹明123和DCFH—DA染色方法测定细胞线粒体膜跨膜电位变化和活性氧（ROS）的产生,用Western印迹检测Bcl-2、Bax蛋白表达的变化。结果：雷公藤甲素对胰腺癌细胞BxPC-3和PANC—1具有生长抑制和诱导细胞凋亡的作用,且呈时间和剂量依赖关系;处理72h后,胰腺癌细胞线粒体跨膜电位明显下降,Bax表达上调,Bcl-2表达下降。结论：雷公藤甲素能有效抑制胰腺癌细胞增殖,通过增强线粒体通透性诱导细胞凋亡。     

西达本胺诱导胰腺癌细胞凋亡

目的：观察西达本胺对胰腺癌细胞BxPC-3和PANC-1生长抑制及诱导细胞凋亡作用,探讨西达本胺抗胰腺癌的机制。方法：西达本胺处理BxPC-3和PANC-1细胞后,用流式细胞术检测细胞的凋亡率,用罗丹明123和DCFH—DA染色方法测定细胞线粒体膜跨膜电位变化和活性氧（ROS）的产生,用Western印迹检测Bcl-2家族和γH2AX蛋白表达的变化。结果：西达本胺对胰腺癌细胞BxPC-3和PANC-1具有生长抑制和诱导细胞凋亡的作用,且呈时间和剂量依赖关系;处理72h后,胰腺癌细胞内ROS产生增强导致DNA损伤发生,且线粒体跨膜电位明显下降;促凋亡蛋白Bax的表达,抑制抑凋亡蛋白Bcl-2和Mcl—1的表达。结论：西达本胺具有抑制胰腺癌细胞增殖,诱导细胞凋亡的作用;西达本胺增强胰腺癌细胞内ROS的产生并导致DNA损伤,最终诱导细胞凋亡的发生。     

Depression of Focal Adhesion Kinase Induces Apoptosis in Rat Osteosarcoma OSR-6 Cells in a Caspase-Dependent Pathway

Focal adhesion kinase (FAK), a nonreceptor tyrosine kinase protein, acts as an early modulator of integrin signaling cascade, regulating basic cellular functions. In transformed cells, unopposed FAK signaling has been considered to promote tumor growth, progression, and metastasis. The aim of this study was to assess the role of FAK in rat osteosarcoma OSR-6 cells. OSR-6 cells were transfected with PGPU6/GFP/shNC (shNC), and PGPU6/GFP/FAK-2434 (shRNA-2434), separately. Expression of FAK was detected by Real-time PCR and Western blots. MTT assay was used to examine changes in cell proliferation. Cell apoptosis was analyzed by flow cytometry. The expression of caspase-3,-7,-9 was measured by Western blots. The expression of FAK in OSR-6 cells significantly decreased in shRNA-2434 group in contrast to the control group (P < 0.01). Cell proliferation was inhibited by shRNA-2434 and shRNA-2434+ cisplatin, and the effects were clearly enhanced when cells were treated with anticancer agents. The level of cell apoptosis in shRNA-2434 and shRNA-2434+ cisplatin group was higher than that in the control group (P < 0.01). The current data support evidence that down-regulation of FAK could induce rat osteosarcoma cells (OSR-6) apoptosis through the caspase-dependent cell death pathway. Inhibition of the kinases may be important for therapies designed to enhance the apoptosis in osteosarcoma.     

Simvastatin Potently Induces Calcium-dependent Apoptosis of Human Leiomyoma Cells

Statins are drugs commonly used for the treatment of high plasma cholesterol levels. Beyond these well known lipid-lowering properties, they possess broad-reaching effects in vivo, including antitumor effects. Statins inhibit the growth of multiple tumors. However, the mechanisms remain incompletely understood. Here we show that simvastatin inhibits the proliferation of human leiomyoma cells. This was associated with decreased mitogen-activated protein kinase signaling and multiple changes in cell cycle progression. Simvastatin potently stimulated leiomyoma cell apoptosis in a manner mechanistically dependent upon apoptotic calcium release from voltage-gated calcium channels. Therefore, simvastatin possesses antitumor effects that are dependent upon the apoptotic calcium release machinery.     

人α－肿瘤坏死因子基因的高效表达

用人工合成的α－肿瘤坏死因子（ＴＮＦ－α）基因构建了五个不同的表达质粒,它们不同之处是ＳＤ序列与起始密码子ＡＴＧ间距离（Ｄ）各异。计算机模拟计算出翻译起始区域（ＴＩＲ）中二级结构的最小生成自由能,以（Ｄ）为６个核苷酸时最小（绝对值）。它的表达效率也最高,产物ＴＮＦ－α可达菌体总蛋白的６０％。密码子的选用对表达效率有很大的影响,故人工合成ＴＮＦ－α基因（选用大肠杆菌偏爱的密码子）的表达效率高于ｓｃ－     

Lysophosphatidic Acid Induces Necrosis and Apoptosis in Hippocampal Neurons

Abstract: A diverse body of evidence indicates a role for the lipid biomediator lysophosphatidic acid (LPA) in the CNS. This study identifies and characterizes the induction of neuronal death by LPA. Treatment of cultured hippocampal neurons from embryonic rat brains with 50 µ M LPA resulted in neuronal necrosis, as determined morphologically and by the release of lactate dehydrogenase. A concentration of LPA as low as 10 µ M led to the release of lactate dehydrogenase. In contrast, treatment of neurons with 0.1 or 1.0 µ M LPA resulted in apoptosis, as determined by chromatin condensation. In addition, neuronal death induced by 1 µ M LPA was characterized as apoptotic on the basis of terminal dUTP nick end-labeling (TUNEL) staining, externalization of phosphatidylserine, and protection against chromatin condensation, TUNEL staining, and phosphatidylserine externalization by treatment with N -benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone, a broad-spectrum inhibitor of caspases, i.e., members of the interleukin-1β converting enzyme family. Studies with antagonists of ionotropic glutamate receptors did not indicate a significant role for these receptors in apoptosis induced by 1 µ M LPA. LPA (1 µ M ) also induced a decrease in mitochondrial membrane potential. Moreover, pretreatment of neurons with cyclosporin A protected against the LPA-induced decrease in mitochondrial membrane potential and neuronal apoptosis. Thus, LPA, at pathophysiological levels, can induce neuronal apoptosis and could thereby participate in neurodegenerative disorders.     

Epithelial-Mesenchymal Transition Induces Endoplasmic-Reticulum-Stress Response in Human Colorectal Tumor Cells

Tumor cells are stressed by unfavorable environmental conditions like hypoxia or starvation. Driven by the resulting cellular stress tumor cells undergo epithelial-mesenchymal transition. Additionally, cellular stress is accompanied by endoplasmic reticulum-stress which induces an unfolded protein response. It is unknown if epithelial-mesenchymal transition and endoplasmic reticulum-stress are occurring as independent parallel events or if an interrelationship exists between both of them. Here, we show that in colorectal cancer cells endoplasmic reticulum-stress depends on the induction of ZEB-1, which is a main factor of epithelial-mesenchymal transition. In the absence of ZEB-1 colorectal cancer cells cannot mount endoplasmic reticulum-stress as a reaction on cellular stress situations like hypoxia or starvation. Thus, our data suggest that there is a hierarchy in the development of cellular stress which starts with the presence of environmental stress that induces epithelial-mesenchymal transition which allows finally endoplasmic reticulum-stress. This finding highlights the central role of epithelial-mesenchymal transition during the process of tumorigenesis as epithelial-mesenchymal transition is also associated with chemoresistance and cancer stemness. Consequently, endoplasmic reticulum-stress might be a well suited target for chemotherapy of colorectal cancers.     

Ubiquitination by the Membrane-associated RING-CH-8 (MARCH-8) Ligase Controls Steady-state Cell Surface Expression of Tumor Necrosis Factor-related Apoptosis Inducing Ligand (TRAIL) Receptor 1

The eleven members of the membrane-associated RING-CH (MARCH) ubiquitin ligase family are relatively unexplored. Upon exogenous (over)expression, a number of these ligases can affect the trafficking of membrane molecules. However, only for MARCH-1 endogenous functions have been demonstrated. For the other endogenous MARCH proteins, no functions or substrates are known. We report here that TRAIL-R1 is a physiological substrate of the endogenous MARCH-8 ligase. Human TRAIL-R1 and R2 play a role in immunosurveillance and are targets for cancer therapy, because they selectively induce apoptosis in tumor cells. We demonstrate that TRAIL-R1 is down-regulated from the cell surface, with great preference over TRAIL-R2, by exogenous expression of MARCH ligases that are implicated in endosomal trafficking, such as MARCH-1 and -8. MARCH-8 attenuated TRAIL-R1 cell surface expression and apoptosis signaling by virtue of its ligase activity. This suggested that ubiquitination of TRAIL-R1 was instrumental in its down-regulation by MARCH-8. Indeed, in cells with endogenous MARCH expression, TRAIL-R1 was ubiquitinated at steady-state, with the conserved membrane-proximal lysine 273 as one of the potential acceptor sites. This residue was also essential for the interaction of TRAIL-R1 with MARCH-1 and MARCH-8 and its down-regulation by these ligases. Gene silencing identified MARCH-8 as the endogenous ligase that ubiquitinates TRAIL-R1 and attenuates its cell surface expression. These findings reveal that endogenous MARCH-8 regulates the steady-state cell surface expression of TRAIL-R1.     

Englerin A Selectively Induces Necrosis in Human Renal Cancer Cells

The number of renal cancers has increased over the last ten years and patient survival in advanced stages remains very poor. Therefore, new therapeutic approaches for renal cancer are essential. Englerin A is a natural product with a very potent and selective cytotoxicity against renal cancer cells. This makes it a promising drug candidate that may improve current treatment standards for patients with renal cancers in all stages. However, little is known about englerin A''s mode of action in targeting specifically renal cancer cells. Our study is the first to investigate the biological mechanism of englerin A action in detail. We report that englerin A is specific for renal tumor cells and does not affect normal kidney cells. We find that englerin A treatment induces necrotic cell death in renal cancer cells but not in normal kidney cells. We further show that autophagic and pyroptotic proteins are unaffected by the compound and that necrotic signaling in these cells coincided with production of reactive oxygen species and calcium influx into the cytoplasm. As the first study to analyze the biological effects of englerin A, our work provides an important basis for the evaluation and validation of the compound''s use as an anti-tumor drug. It also provides a context in which to identify the specific target or targets of englerin A in renal cancer cells.